Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
24 Arthritis Trials near Birmingham, AL
Power is an online platform that helps thousands of Arthritis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerDapansutrile for Gout Flares
Birmingham, Alabama
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Tophi, Rheumatoid Arthritis, Kidney Disease, Others
Must Not Be Taking:Paracetamol, Acetaminophen, Others
300 Participants Needed
Upadacitinib for Rheumatoid Arthritis
Birmingham, Alabama
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Adalimumab, Inadequate BDMARD Response, Others
Must Be Taking:Methotrexate
1629 Participants Needed
Opioid Taper Before Surgery for Arthritis
Birmingham, Alabama
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are:
* Is the intervention feasible and acceptable to patients?
* Does the intervention result in a decrease in opioid dose during the preoperative period?
Participants will meet with a clinical pharmacist, who will provide some basic education on pain and opioids, and will propose an opioid taper schedule. The pharmacist will then follow-up with the participant by phone each week until surgery to assess progress and adjust the taper as necessary.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Non-English Speakers, Others
Must Be Taking:Opioids
45 Participants Needed
Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis
Birmingham, Alabama
This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:HIV, Heart Failure, Hepatitis, Others
Must Be Taking:TNFi-biologic
924 Participants Needed
Deucravacitinib for Psoriatic Arthritis
Mountain Brook, Alabama
This trial is testing a new medication called deucravacitinib to help people with active Psoriatic Arthritis. It aims to reduce joint pain and swelling by blocking harmful signals in the body. The study includes people who haven't tried biologic treatments or need an alternative to TNFα inhibitors. Deucravacitinib is an emerging treatment option for Psoriatic Arthritis, showing promise in recent studies.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Nonplaque Psoriasis, Lupus, Fibromyalgia, Others
Must Not Be Taking:Biologics
729 Participants Needed
Guselkumab for Psoriatic Arthritis
Birmingham, Alabama
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Rheumatoid Arthritis, Lupus, Others
Must Not Be Taking:Biologics, JAK Inhibitors
1054 Participants Needed
Enekinragene Inzadenovec for Knee Arthritis
Birmingham, Alabama
The goal of this clinical trial is to learn if a single knee injection of different doses (Dose A and Dose B) of an investigation product PCRX-201, following steroid pretreatment, is safe and tolerable in male of female patients 45 to 80 years old with osteoarthritis of the knee. It will also learn how the body reacts to the PCRX-201 injection and how effective the treatment is.
Researchers will compare Dose A and Dose B of PCRX-201 versus placebo from Week 1 through Week 52 to assess adverse events. Researchers will also explore how PCRX-201 may impact knee pain and joint function over time.
Participants will be asked to
* Visit the clinic for pretreatment and drug administration
* Visit the clinic for checkups and tests:
1. Screening through Week 52: intially weekly, bi-weekly, later monthly
2. Week 53 through Week 260 (Year 5): 8 visits throughout the period
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:45 - 80
Key Eligibility Criteria
Disqualifiers:Autoimmune Disorders, Infections, Unstable Knee, Others
Must Be Taking:Steroids
135 Participants Needed
TNFi Therapy Strategies for Juvenile Spondyloarthritis
Birmingham, Alabama
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 29 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:8 - 21
Key Eligibility Criteria
Disqualifiers:Inflammatory Bowel Disease, Uncontrolled Uveitis, Psoriasis, Others
Must Be Taking:TNFi Therapies
164 Participants Needed
TTAX03 Injection for Knee Osteoarthritis
Birmingham, Alabama
This trial tests if a single injection of TTAX03 in saltwater can improve knee conditions better than just saltwater. It targets patients needing knee injections and checks their response over a few months.
Trial Details
Trial Status:Active Not Recruiting
Age:35 - 85
Key Eligibility Criteria
Disqualifiers:Not Listed
90 Participants Needed
Mindfulness + tDCS for Osteoarthritis
Birmingham, Alabama
This mechanistic clinical trial proposes to test whether a five-day course of mindfulness meditation training (MMT) and tDCS, and their combination, can enhance pain modulatory balance and pain-related brain function, reduce clinical pain, among African Americans and non-Hispanic whites with knee osteoarthritis (OA). This approach will provide evidence that targeting stress and pain-related brain function will reduce OA-related pain and ethnic group differences therein.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:45 - 85
Key Eligibility Criteria
Disqualifiers:Not Listed
240 Participants Needed
AR882 for Gout
Birmingham, Alabama
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Malignancy, Pregnant, Kidney Stones, Others
750 Participants Needed
Bimekizumab for Plaque Psoriasis
Birmingham, Alabama
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Active Infections, Tuberculosis, Malignancy, Others
90 Participants Needed
Ustekinumab/Guselkumab for Juvenile Psoriatic Arthritis
Birmingham, Alabama
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:5 - 17
Key Eligibility Criteria
Disqualifiers:Enthesitis-related Arthritis, Tuberculosis, Others
Must Be Taking:Methotrexate, Sulfasalazine
48 Participants Needed
SakuraBead Embolization for Osteoarthritis
Birmingham, Alabama
An open label, prospective, two-arm, multicenter, randomized controlled trial comparing SakuraBead genicular artery embolization (GAE) with a control (corticosteroid injection).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:40 - 79
Key Eligibility Criteria
Disqualifiers:Severe Knee OA, Autoimmune Arthritis, Others
89 Participants Needed
Emapalumab for MAS in Still's Disease or Lupus
Birmingham, Alabama
This trial is testing emapalumab, a medication that helps control an overactive immune system, in children and adults with certain immune conditions who haven't responded to high-dose steroids. The goal is to see if it is safe and effective in reducing excessive inflammation. Emapalumab is a monoclonal antibody that targets interferon-γ and was first approved for treating primary hemophagocytic lymphohistiocytosis (HLH) in patients with refractory, recurrent, or progressive disease.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:6 - 80
Key Eligibility Criteria
Disqualifiers:Primary HLH, Malignancy, Active Infections, Others
Must Be Taking:Glucocorticoids
41 Participants Needed
Hip Implant for Hip Replacement
Birmingham, Alabama
The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Infection, Osteoporosis, Metabolic Disorders, Others
202 Participants Needed
Nivolumab for Cancer
Birmingham, Alabama
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Chemotherapy, Radiotherapy, Allogeneic Transplant, Others
Must Not Be Taking:Anticancer Investigational Agents
300 Participants Needed
BMS-986278 for Pulmonary Fibrosis
Birmingham, Alabama
The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:21+
Key Eligibility Criteria
Disqualifiers:Idiopathic Pulmonary Fibrosis, Stroke, Heart Failure, Current Malignancy, Others
Must Not Be Taking:Systemic Corticosteroids
1092 Participants Needed
Amniotic Suspension Allograft for Osteoarthritis
Birmingham, Alabama
This trial is testing a new treatment called ASA, which is injected directly into the knee joint. It aims to help patients with knee osteoarthritis by reducing pain and improving joint function. The study will compare the effects of ASA over several months.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Knee Surgery, Immunosuppressive Therapy, Others
Must Not Be Taking:NSAIDs, Anticoagulants, Corticosteroids, Others
474 Participants Needed
Subtalar Arthrodesis for Calcaneus Fractures
Birmingham, Alabama
Management of severe injuries to the heel (displaced intra-articular calcaneus fractures) continues to be a major challenge for orthopedic surgeons. Previous studies have demonstrated poor outcomes, and results show that patients experience long-term pain and decreased quality of life postoperatively. Poor outcomes are driven by pain, in particular, which is linked to post-traumatic subtalar arthritis.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:BMI >40, Non-English/Spanish, Prisoner, Others
218 Participants Needed
Why Other Patients Applied
"I am an active athlete who is not ready or willing to stop my activities because of knee pain at 42. I have tried cortisone shots and found they only temporary mask the issue, or even cause more problems later. That's why I started researching medical studies."
GM
Arthritis PatientAge: 44
"I’m allergic to so many standard arthritis drugs, so I've been researching some of the newest ones still in the research phase. I'm hoping to find out if I'd be a good match—it would be great to find something that works (and, if not, at least contribute to the cause)."
TJ
Arthritis PatientAge: 79
"I've been 17+ years in pain with bilateral osteoarthritis. PRP and HA injections have not helped. Physical therapy has helped only to a certain degree. I'm looking for new treatment options before considering replacement. "
RH
Arthritis PatientAge: 39
"I have been struggling with severe knee pain since my service in the military. I am only 52! I miss doing the things I used to do."
NA
Arthritis PatientAge: 55
"I’ve tried several meds without too much relief. Injections only work on my right knee but not much on the left knee. My pain is nearly unbearable at this point. Hoping to learn about what promising drugs exist in trials."
YV
Arthritis PatientAge: 61
Amniotic Suspension Allograft for Knee Osteoarthritis
Birmingham, Alabama
This trial is testing if injecting ASA into the knee can help people with knee osteoarthritis feel better. The study will check pain levels, knee function, and safety over several months. ASA (Amniotic Suspension Allograft) has been shown to be an effective treatment for knee osteoarthritis in previous studies.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:19+
Sex:Male
Key Eligibility Criteria
Disqualifiers:Knee Surgery, Infection, Substance Use, Others
Must Not Be Taking:Anticoagulants, Immunosuppressives, Steroids
474 Participants Needed
ZILRETTA for Shoulder Osteoarthritis
Vestavia Hills, Alabama
Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo
Secondary Objective:
* To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, and normal saline placebo
* To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:50 - 80
Key Eligibility Criteria
Disqualifiers:Symptomatic Arthritis, Rotator Cuff Pathology, Chronic Shoulder Pain, Others
Must Not Be Taking:Opioids, Analgesics, THC/CBD, SSRIs/SNRIs
150 Participants Needed
Peresolimab for Rheumatoid Arthritis
Birmingham, Alabama
This trial is testing a new medication called peresolimab to see if it is safe and effective for adults with moderate to severe rheumatoid arthritis. The medication aims to reduce inflammation and joint damage by calming the immune system.
Trial Details
Trial Status:Active Not Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
491 Participants Needed
AlloNK + Rituximab for Rheumatic Diseases
Tuscaloosa, Alabama
A Basket Trial of Refractory Rheumatoid Arthritis (RA), Sjögren's Disease (SjD), Idiopathic Inflammatory Myopathies (IIMs) and Systemic Sclerosis (SSc) subjects to evaluate the safety and efficacy of AlloNK, a non-genetically modified allogeneic NK cell, in combination with rituximab.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, Hypertension, Bipolar, Others
Must Be Taking:Biologic DMARDs
90 Participants Needed
Know someone looking for new options?
Spread the word